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Cyclosporin A (CsA)-induced gingival overgrowth is one of 
the major side effects affecting the quality of life of patients 
under immunosuppressive therapy, but lip enlargement is less 
frequently recognized. CsA affects T lymphocytes, which play 
a pivotal role in the periodontal antibacterial immune 
response.
The authors present a case of marked gingival hypertrophy 
associated with lip hypertrophy (Image 1) in a 19-year-old man 
with severe aplastic anemia treated with CsA. The daily dose 
of CsA was 4 mg/kg body weight. CsA improved the clinical 
and hematological signs of aplastic anemia.
The development of this adverse effect appeared three 
months after beginning the immunosuppressive treatment with 
CsA [1].
The patient received a 14-day course of metronidazole, 
500 mg three times daily. One month after the end of this 
therapy, the grade of gingival hypertrophy (according to the 
grading method of Matarasso) had improved from grade 3 to 
grade 1, and the lip hypertrophy had disappeared. Over the 
next one month, the condition remitted completely and had not 
recurred.
This rare and less understood adverse effect should be 
recognized during the clinical evaluation of CsA treatment.
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Image 1. Gingival and lip hypertrophy induced by cyclosporin A treat-
ment in an aplastic anemia patient